Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields

Published 27/03/2024, 12:13
Updated 27/03/2024, 13:40
© Reuters.  Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy .

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Johnson & Johnson (NYSE: JNJ)

  • Dividend Yield: 3.06%
  • Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $170 to $169 on Jan. 24, 2024. This analyst has an accuracy rate of 67%.
  • Raymond James analyst Jayson Bedford maintained an Outperform rating and boosted the price target from $172 to $175 on Jan. 3, 2024. This analyst has an accuracy rate of 67%.
  • Recent News: Johnson & Johnson is reportedly in talks to acquire Shockwave Medical, Inc (NASDAQ: SWAV).
Patterson Companies, Inc.
  • Dividend Yield: 3.85%
  • Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $38 to $35 on Nov. 30, 2023. This analyst has an accuracy rate of 77%.
  • Stifel analyst Jonathan Block reiterated a Hold rating with a price target of $32 on Nov. 28, 2023. This analyst has an accuracy rate of 77%.
  • Recent News: On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
  • Dividend Yield: 4.25%
  • Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $84 to $77 on March 4, 2024. This analyst has an accuracy rate of 76%.
  • RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and lowered the price target from $76 to $75 on Feb. 14, 2024. This analyst has an accuracy rate of 71%.
  • Recent News: On March 22, Gilead Sciences announced completion of acquisition of CymaBay.

Read More: GameStop Posts Downbeat Results, Joins Direct Digital, Forge Global And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.